Our Leadership Team

Stephen Perry

Stephen M. Perry


Founder & CEO


Stephen Perry LinkedIn
Kymanox is led by Chief Executive Officer and Founder, Stephen M. Perry, who has over two decades of experience in biopharmaceutical manufacturing with an emphasis on design engineering, scale-up, start-up, and regulatory approval. Stephen has participated in the FDA commercial approval of more than two dozen unique drugs, devices, biologics, and combination products. Stephen has extensive cGMP experience as a Process Engineer, Technical Project Manager, Quality Manager, Regulatory Auditor, and Information Technology Strategist. His work with novel cancer drugs, including autologous cell and gene therapies, and next generation antibiotics are notable from a technology transfer perspective. Stephen has led numerous multi-million-dollar capital projects and has contributed to several major facility installations and qualifications, which began at the conceptual design phase. He has also designed two novel equipment systems related to virus filtration that included full automation.

In 2004, Stephen created Kymanox as a service-centric firm specializing in commercializing modern medicine and making new and better therapies available to patients in need. Starting with a small investment and large commitment, Stephen has strategically positioned Kymanox into a nationally recognized organization serving national and international companies in biotechnology, pharmaceuticals, medical devices and combination products. The core business of Kymanox is professional services with an emphasis on turnkey technical and compliance solutions for product commercialization. Furthering his commitment to teaching the next generation, Stephen created the Kymanox Academy, a leadership development program for recent graduates that trains and develops them in the Life Science space quickly, efficiently, and with good habits. Prior to Kymanox, Stephen had various leadership roles supporting scale-up, start-up, and commercialization initiatives at M+W Group, Abbott Laboratories, FujiFilm Diosynth Biotechnologies, and Human Genome Sciences.

Stephen has been a keynote speaker at national and international biotech and pharma conferences and has authored articles for industry and news publications. He advises several companies at the C-suite level and has served on the board of directors of publicly traded companies. Stephen is an industry-recognized instructor in several subject areas, including technology transfer and scale-up. He has also conducted and supervised more than 100 audits around the globe for supplier quality, mock PAIs, and quality management system optimization.  Stephen is a long-time supporter of the Regulatory Affairs Professional Society (RAPS), International Society of Pharmaceutical Engineering (ISPE), Parental Drug Association (PDA), and the Project Management Institute (PMI). He graduated with high honors with a bachelor’s degree in Chemical Engineering from the University of Notre Dame and studied at the graduate level at Purdue University.

Stephen Perry

Stephen M. Perry


CEO and Founder


Stephen Perry LinkedIn

Stephen M. Perry is the founder of Kymanox – a diversified company specializing in technical project management for the Pharmaceutical, Biotechnology and Medical Device industries – as well as Sustainability and Nanotechnology. Stephen has extensive cGMP experience as a Process Engineer, Technical Project Manager, Quality Manager, Regulatory Auditor, and Information Technology Strategist. He has hired over 300 professionals in his career and currently oversees a team of more than 100.

Before starting Kymanox in 2004, Stephen had various leadership roles supporting scale-up, start-up, and commercialization initiatives at Abbott Laboratories, FujiFilm Diosynth Biotechnologies, and Human Genome Sciences.

During his career, Stephen participated with increasing responsibilities in the FDA commercial approval of 15 unique drugs, devices, biologics, and combination products. Stephen’s work with novel cancer drugs, including autologous cell and gene therapies, and next generation antibiotics are notable from a technology transfer perspective. Stephen has led numerous multi-million dollar capital projects and has contributed to several major facility installations and qualifications which began at the conceptual design phase. Stephen has also designed two novel equipment systems related to virus filtration which included full automation.

Stephen has experience supporting quality assurance and regulatory initiatives related to medical devices and combination products, including successful filings and responses to FDA. Stephen is an industry-recognized instructor and author in several subject areas, including technology transfer, and speaks regularly at industry events throughout the world. Stephen has conducted and supervised more than 100 audits around the globe for supplier quality, mock PAIs, and quality management system optimization.

Stephen has a liberal education background with a high-honors bachelor’s degree in Chemical Engineering from the University of Notre Dame and studied at the graduate level at Purdue University.  Stephen is a long-time supporter of the Regulatory Affairs Professional Society (RAPS), International Society of Pharmaceutical Engineering (ISPE), Parental Drug Association (PDA), and the Project Management Institute (PMI).

Blog articles:
Kymanox partners with Shire at CPhI North American Conference

Biotechnology | Pharmaceuticals | Medical Devices | Combination Products